Agreements - Lilly (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 28, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Collaborative Agreements disclosures
Aggregate amount of transaction price allocated to remaining performance obligations		$ 59,200		$ 59,200
Revenue from contract with customer		14,162	$ 16,948	52,240	$ 32,654
Amount of obligation included in long-term deferred revenue		43,611		43,611		$ 47,717
Lilly
Collaborative Agreements disclosures
License agreement upfront payment receivable	$ 13,000
License agreement additional payment receivable	$ 32,500
License agreement additional target term	4 years
License agreement, target selection fees and development, regulatory and commercial milestone payments receivable	$ 1,700,000
Aggregate amount of transaction price allocated to remaining performance obligations	13,000
Lilly | Upfront payment
Collaborative Agreements disclosures
Estimated payments to received	13,000
Lilly | Initial targets
Collaborative Agreements disclosures
Revenue from contract with customer	9,200			9,200
Lilly | Material rights to obtain licenses to replacement targets
Collaborative Agreements disclosures
Revenue from contract with customer	$ 3,800
Amount of obligation included in long-term deferred revenue		$ 3,800		$ 3,800